Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Clinical trial NCT04521153 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04521153
Sponsor: Shanghai Zhongshan Hospital
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Immunotherapy Molecular Targeted Therapy

Start date: 2021-03-25
Primary completion: 2025-07-31
Enrollment: 294

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.